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ABSTRACT 
Background: The results of previous studies suggested that there is an increased risk of patent ductus arteriosus (PDA) in 
the neonates with lower serum cortisol levels. This study aimed to assess the association between serum cortisol values 
and PDA and investigate if there is an association between PDA and the antenatal administration of betamethasone. 
Methods: The present study was carried out on the neonates with gestational age between 28 to 35 weeks. The 
prenatal administration of betamethasone to the mothers was extracted from the records. A pediatric cardiologist 
performed an echocardiographic assessment on the second day of life (DOL) and fifth DOL and the infants were 
evaluated for the presence of PDA. The blood samples were obtained on the second and fifth DOL and serum cortisol 
levels were measured. We evaluated the association between serum cortisol levels and PDA. Also, the correlation 
between PDA and the antenatal administration of betamethasone was assessed. 
Results: The mean scores of serum cortisol levels on the second DOL in the neonates with and without PDA were 
4.99±2.69 (μg/dl) and 7.23±2.87 (μg/dl), respectively that were significantly lower in the first group, compared to 
those of the second group. However, the mean levels of serum cortisol in the neonates with and without the prenatal 
administration of betamethasone were not significant (P=0.522). 
Conclusion: We have concluded that lower serum cortisol level was associated with the increase in the risk of PDA and 
the prenatal administration of glucocorticoids may not reduce the occurrence of PDA. 
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Introduction 
Patent ductus arteriosus (PDA) is one of the 
most common congenital heart defects that 
results in the persistent left-to-right shunt 
between the descending aorta and pulmonary 
artery (1, 2). The functional closure of the ductus 
arteriosus in term infants happens in the first 72 
h of life, although its closure may be delayed in 
premature neonates (3, 4). 
The results of the previous studies suggested 
that there is an increased risk of PDA in the 
neonates with lower serum cortisol levels (5). It 
has been proposed that ill premature infants may 
have lower serum cortisol levels due to insufficient 
adrenal response to stress because of immaturity 
in the development of the hypothalamic-pituitary-
adrenal axis (6). 
The findings of several studies have 
demonstrated the benefits of antenatal 
administration of glucocorticoids (7, 8). Based on 
the previous animal studies, it has been proposed 
Khosravi N et al        Evaluation of Cortisol Level in Premature Neonates 
 
 
2  Iranian Journal of Neonatology 2019; 10(1)  
that prenatal corticosteroids have a constrictive 
effect on the ductus arteriosus of the fetus (9, 10) 
that may be due to a change in the response of 
the ductus muscle to the prostaglandin E2 
(PGE2) (11). Therefore, it has been suggested 
that PDA may be less frequent in the neonates 
whose mothers have been prenatally treated 
with corticosteroids (12). This study aimed to 
assess the association between serum cortisol 
levels and PDA and investigate the association 




The Institutional Review Board/Ethics 
Committee of Iran University of Medical Sciences 
approved this observational cross-sectional study. 
The present study was conducted on all the 
neonates with a gestational age of 28 to 35 weeks, 
regardless of their birth weight admitted to 
neonatal intensive care unit in Akbar Abadi 
hospital over a one-month period between 
December 2016 and January 2017. The infants 
with neonatal sepsis, major congenital anomalies, 
and major heart defects, except for PDA, were 
excluded from this study. The parents signed an 
informed consent form.  
The related previous history was reviewed and 
the prenatal administration of betamethasone to 
the mothers was extracted from the records. A 
pediatric cardiologist  who was masked from the 
study protocol performed an echocardiographic 
assessment on the second and fifth days of life 
(DOL) and the infants were evaluated for the 
presence of PDA. No infants received treatment 
for PDA since none of them showed any signs of 
overt congestive heart failure or cardiovascular 
instability.  
Two blood samples were obtained in the 
mornings on the second and fifth DOL and serum 
cortisol levels were measured in a single laboratory 
setting using cortisol RIA kit (IMMUNOTECH s.r.o, 
Czech Republic). We evaluated the association 
between serum cortisol levels and PDA. Also, the 
correlation between PDA and the antenatal 
administration of betamethasone was assessed. We 
also evaluated whether the prenatal corticosteroid 
administration has an effect on serum cortisol level 
in the first week of life in infants. 
 
Statistical Methods 
To present the quantitative data, we used 
mean and standard deviation, and the qualitative 
data were reported in percentage. To evaluate the 
subject’s parameters between the groups we used 
t-test and Chi-square test. All statistical analyses 
were performed by SPSS software (IBM Corp. 
Released 2013. IBM SPSS statistics for windows, 
version 22.Armonk, NY: IBM Corp.). P-value less 
than 0.05 was statistically considered significant. 
 
Results 
From 30 premature neonates included in this 
study based on eligibility, 22 (73.33%) cases had 
serum cortisol levels lower than 6.5 μg/dl in the 
primary evaluation on the second DOL and in this 
group, 19 neonates (86.36%) had PDA in the first 
echocardiography. From eight neonates with 
serum cortisol levels more than 6.5 μg/dl, 5 
neonates (62.5%) had PDA. 
The mean scores of serum cortisol levels in the 
second DOL in neonates with and without  
PDA were 4.99±2.69 and 7.23±2.87 (μg/dl), 
respectively that was significantly lower in the 
first group, compared to those of the second group 
(P=0.044) (Figure 1). It was shown that 19 out of  
 
 
Figure 1. Mean cortisol level in the second day of life in neonates with and without patent ductus arteriosus 
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Figure 2. Mean cortisol level in the fifth day of life in neonates with and without patent ductus arteriosus 
 
24 (79%) neonates with PDA and 3 out of 6 (50%) 
neonates without PDA had serum cortisol level 
less than 6.5 in the second DOL. Furthermore, the 
mean values of serum cortisol levels in the fifth 
DOL in the neonates with and without PDA were 
11.63±5.09 and 9.87±3.99 (μg/dl), respectively 
that was not significant (P=0.750) (Figure 2).  
In the fifth DOL, 12.5% and 16.7% of the 
neonates with and without PDA had serum 
cortisol values less than 6.5. The mean scores of 
serum cortisol difference between the second and 
fifth DOL were 6.63±4.43 and 3.76±2.63 in the 
neonates with and without PDA, respectively. This 
difference was significantly higher in the group of 
neonates with PDA, compared to the group of 
neonates without PDA (P=0.025). 
Out of 30 premature neonates, 17 cases were 
born from mothers that have been antenatally 
given betamethasone. On the second DOL, the 
mean values of serum cortisol levels in the 
neonates with and without the prenatal 
administration of betamethasone were 5.15±2.86 
and 5.83±2.86 (μg/dl), respectively, and the 
difference was not significant (P=0.522). 
Thirteen neonates with a history of prenatal 
betamethasone administration had serum 
cortisol levels less than 6.5 on the second DOL, 
although this level of serum cortisol was evident 
in 11 neonates without a history of prenatal 
betamethasone. Therefore, there was no 
significant difference between these two groups 
(P=0.087).  
Furthermore, the mean scores of serum 
cortisol levels in the neonates with and without 
the prenatal administration of betamethasone 
were 11.74±5.36 and 10.68±4.31 (μg/dl), 
respectively in the fifth DOL, and the difference 
was not significant (P=0.565). 
In the fifth DOL, three neonates with a history 
of prenatal betamethasone administration had a 
serum cortisol level less than 6.5 μg/dl that was 
reported only in one neonate with no history  
of prenatal administration of betamethasone 
(P=0.132). The mean scores of serum cortisol 
difference between the second and fifth DOL in  
the neonates with and without prenatal 
administration of betamethasone were 6.59±4.84 
and 4.85±4.09, respectively, and the difference 
was not significant (P=0.603). 
The diagnoses of PDA in the first and second 
echocardiographic assessments were observed in 
24 (80%) and 5 (16.7%) cases, respectively that 
was significantly higher in the first assessment, 
compared to the second one (P=0.033). Based on 
echocardiographic findings, PDA was resolved in 
19 out of 24 neonates with PDA in the primary 
assessment.  
The mean values of cortisol levels on the 
second DOL in the neonates with PDA without 
change, PDA that resolved spontaneously, and 
without PDA were 5.38±3.05, 4.89±2.67, and 
7.23±2.87 (μg/dl), respectively, and there was no 
significant difference between these groups 
(P=0.216). Moreover, the mean scores of serum 
cortisol levels on the fifth DOL in the neonates 
with PDA without change, PDA that resolved 
spontaneously, and without PDA were 7.86±3.91, 
12.62±4.97, and 9.87±3.99 (μg/dl), respectively 
(P=0.109). 
The mean values of serum cortisol level 
difference between the second and fifth DOL in the 
neonates with PDA without change, PDA that 
resolved spontaneously, and without PDA were 
2.84±1.81, 7.73±4.28, and 5.83±4.54 (μg/dl), 
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respectively. These differences between the 
second and fifth DOL were significantly higher in 
the neonates with PDA that was spontaneously 
resolved, compared to other cases (P=0.006). In 
the neonates born from mothers that were given 
prenatal betamethasone, PDA remained without 
any changes in 80% of the cases, although PDA 
was spontaneously resolved in 47.7% of the 
neonates and 66.6% of the cases had no sign of 




In this study, we assessed the association 
between serum cortisol values and PDA and 
between PDA and the antenatal administration of 
betamethasone. Moreover, it was investigated 
whether prenatal corticosteroid administration 
has an effect on serum cortisol level in the first 
week of life in premature infants. It was observed 
that lower serum cortisol values were associated 
with higher risk of PDA in the second DOL but not 
in the fifth DOL suggesting a compensatory 
increase in serum cortisol levels during the first 
week of life.  
Watterberg et al. have also demonstrated that 
lower cortisol levels are associated with higher 
risk of PDA (5). They have found a reduction in 
serum cortisol values in the first week of life 
whereas in the present study there was an 
increase in serum cortisol level in the second and 
fifth DOL that was associated with spontaneous 
closure of PDA. Also, it was found that the 
difference between serum cortisol in the second 
and fifth DOL was significantly higher in the 
neonates with PDA, compared to those without 
PDA suggesting the previous statement on the 
negative correlation between serum cortisol and 
PDA. 
Although in the previous studies, it has been 
proposed that prenatal administration of 
corticosteroids might affect the neonatal level of 
serum cortisol (13). In this study, there was no 
correlation between prenatal corticosteroids and 
neonatal serum cortisol levels in the second and 
fifth DOL. In the present study, there was no 
association between the prenatal administrations 
of betamethasone and PDA incidence in the 
infants whereas Waffarn et al. and Eronen et al. 
have proposed in different studies that prenatal 
corticosteroids reduce the risk of PDA (8, 12).  
This association may be caused by the effects 
of the glucocorticoids on the sensitivity of the 
ductus arteriosus muscle to PGE2 (14). The results 
of other studies also stated that the administration 
of prenatal corticosteroids might improve the 
cardiovascular system and lower the risk of PDA 
(7, 15). This difference between the results of the 
present study and mentioned studies is maybe 
due to later administration of betamethasone to 
some of the mothers that caused a reduction in the 
effectiveness of this drug. 
There were some limitations in the present 
study. Since the study population was small, the 
results might have low generalizability. Another 
limitation was the observational nature of this 
study. It is recommended to carry out further 
studies with a larger population and with clinical 




In the end, it was concluded that lower serum 
cortisol level was associated with the increase in 
the risk of PDA, and the prenatal administration of 
glucocorticoids had no effect on serum cortisol 
level in the first week of life and did not reduce the 
occurrence of PDA. 
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